• Spero Therapeutics scheduled 2026 annual stockholder meeting for June 23, 2026, to be held virtually via live audio webcast.
• Shareholders will vote on election of two directors for terms running to 2029.
• Ballot includes ratification of PricewaterhouseCoopers as independent auditor for fiscal year ending Dec. 31, 2026.
• Items also include advisory vote on executive compensation.
• Proposals cover an increase in authorized common shares to 240,000,000 from 120,000,000, plus adoption of 2026 stock incentive plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-153115), on April 13, 2026, and is solely responsible for the information contained therein.